Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: radiolabelled edotreotide - Progenics Pharmaceuticals

Next Previous
Drug Profile

Research programme: radiolabelled edotreotide - Progenics Pharmaceuticals

Alternative Names: DOTA-Tyr3-octreotide - Progenics Pharmaceuticals; Edotreotide - Progenics Pharmaceuticals; Radiolabelled DOTA-TOC - Progenics Pharmaceuticals

Latest Information Update: 19 Jun 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unknown
  • Developer ITM Group; Progenics Pharmaceuticals
  • Class Cyclic peptides; Organotechnetium compounds; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Somatostatin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Neuroendocrine tumours

Most Recent Events

  • 16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings
  • 18 Sep 2013 Edotreotide and certain radiolabelled edotreotide products sublicensed to itm Group worldwide (excluding Albania, Algeria, Bahrain, Bulgaria, Cyprus, Greece, Iran, Iraq, Kuwait, Lebanon, Oman, Qatar, Romania, Saudi Arabia, Syria, Turkey and United Arab Emirates)
  • 18 Sep 2013 Investigation in Neuroendocrine tumours in Germany (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top